Patients with bone metastases or lesions secondary to solid tumors or multiple myeloma often experience bone complications (skeletal-related events [SREs] - radiation to bone, pathologic fracture, surgery to bone and spinal cord compression); however, recent data that can be used to assess the value of treatments to prevent SREs across European countries are limited.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
This study aimed to provide estimates of health resource utilization (HRU) and cost associated with all SRE types in Europe. HRU data were reported previously; cost data are reported herein.
Eligible patients from 49 centers across Austria (n=57), the Czech Republic (n=59), Finland (n=60), Greece (n=59), Portugal (n=59) and Sweden (n=62) had bone metastases or lesions secondary to breast, lung or prostate cancer, or multiple myeloma, and ≥1 index SRE (a SRE preceded by a SRE-free period of ≥6. 5 months). SRE-related costs were estimated from a payer perspective using health resource utilization data from patient charts (before and after the index SRE diagnosis). Country-specific unit costs were from 2010 and local currencies were converted to 2010 euros.
The mean costs across countries were €7,043, €5,242, €11,101 and €11,509 per radiation to bone, pathologic fracture, surgery to bone and spinal cord compression event, respectively. Purchasing power parity (PPP)-adjusted mean cost ratios were similar in most countries, with the exception of radiation to bone.
The overall burden of SREs may have been underestimated owing to home visits and evaluations outside the hospital setting not being reported here.
All SREs were associated with substantial costs. Variation in SRE-associated costs between countries was most likely driven by differences in treatment practices and unit costs.
Journal of medical economics. 2016 Feb 05 [Epub ahead of print]
J Pereira, J-J Body, O Gunther, H Sleeboom, G Hechmati, N Maniadakis, E Terpos, Y P Acklin, J Finek, R von Moos
a Universidade NOVA de Lisboa, National School of Public Health, Public Health Research Centre (CISP) , Lisbon , Portugal. , b C. H. U. Brugmann, Université Libre de Bruxelles , Brussels , Belgium. , c Centre for Observational Research, Amgen Ltd , Uxbridge , UK. , d HAGA Hospital , The Hague , The Netherlands. , e Health Economics, Amgen (Europe) GmbH , Zug , Switzerland. , f Department of Health Services Management , National School of Public Health , Athens , Greece. , g University of Athens School of Medicine, Alexandra University Hospital , Athens , Greece. , h Kantonsspital Graubünden , Chur , Switzerland. , i University Hospital , Plzen , Czech Republic. , h Kantonsspital Graubünden , Chur , Switzerland.